Navigation Links
Amgen to Present at the 27th Annual JP Morgan Healthcare Conference

THOUSAND OAKS, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will present at the 27th Annual JP Morgan Global Healthcare Conference at 9:00 a.m. Pacific Time on Monday, Jan. 12, 2009, at the Westin St. Francis in San Francisco, Calif. Amgen Chairman and CEO Kevin Sharer will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site,, under Investors.


Information regarding presentation time, webcast availability, and webcast links are available on Amgen's Investor Relations Events Calendar.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit

    CONTACT: Amgen, Thousand Oaks
    David Polk, 805-447-4613 or 805-490-0661 (media)
    Arvind Sood, 805-447-1060 (investors)

Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
2. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
3. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
4. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
5. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Amgen Announces Webcast of 2008 Third Quarter Financial Results
8. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
9. Call for Applications: The Amgen Award for Science Teaching Excellence
10. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
11. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... ... (HIFU) technologies, announced today that it received de novo clearance from the U.S. ... U.S. for the ablation of prostate tissue. Sonablate® is the first High Intensity ...
(Date:10/13/2015)... Jersey (PRWEB) , ... October 13, 2015 , ... ... enhance the educational opportunities for school age children in the areas of Science, ... for all sectors of the national economy, and the program aims to increase ...
(Date:10/12/2015)... Calif. and BRUSSELS , Oct. ... (Euronext Brussels: UCB) today presented additional findings from an exploratory ... The findings were presented today in an oral plenary ... (ASBMR) 2015 Annual Meeting in Seattle . ... --> The small exploratory sub-study data showed ...
(Date:10/12/2015)... Ga. , Oct.12, 2015  MiMedx Group, Inc. ... utilizing human amniotic tissue and patent-protected processes to develop ... Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and the ... complaint which had been filed against the Company has ... H. Petit , Chairman and CEO, stated, "As we ...
Breaking Biology Technology:
(Date:9/30/2015)... BEACH GARDENS, Fla. , Sept. 30, 2015 /PRNewswire/ ... earlier this month issued another key ruling in favor ... (ITC,s) determination that Korean fingerprint scanner company Suprema and ... Tariff Act of 1930, a trade provision that declares ... with import trade, by infringing two of Crossmatch,s patents, ...
(Date:9/28/2015)... , Sept. 28, 2015  The monitoring of ... and body temperature, is an essential component of ... indicators of deterioration in a patient,s condition. However, ... signs are typically taken during routine observation rounds ... a patient deteriorates between these observation rounds, the ...
(Date:9/24/2015)...  EyeLock LLC, a market leader of iris-based identity ... latest technology in Booth #602 at next week,s ASIS ... EyeLock,s iris authentication technology provides an unprecedented level ... it the most proven way to authenticate one,s identity ... deliver a fast and friendly user experience to identify ...
Breaking Biology News(10 mins):